Snca A53T is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The A53T (p.Ala53Thr) mutation in the SNCA (Alpha-Synuclein) gene was the first genetic cause of Parkinson's disease identified. This highly penetrant mutation causes autosomal dominant PD with a characteristic aggressive phenotype.
| Property | Value |
|---|---|
| Gene | SNCA |
| Nucleotide Change | c.157C>A |
| Protein Change | p.A53T |
| Chromosomal Location | 4q21 |
| Inheritance | Autosomal Dominant |
| Penetrance | ~85% by age 80 |
| Population | Frequency | Origin |
|---|---|---|
| Italian | 0.1% | Contursi family cluster |
| Korean | 0.05% | Rare |
| Japanese | Rare | Few families |
| Other | Very rare | Founder effect |
The A53T mutation originated from a common founder, most extensively studied in the Italian Contursi family.
Alpha-synuclein is a natively unfolded protein enriched in presynaptic terminals:
| Feature | SNCA A53T PD | Idiopathic PD |
|---|---|---|
| Age of onset | 45±10 years | 62±10 years |
| Disease duration | 9±4 years | 15±5 years |
| Tremor onset | 60% | 75% |
| Bradykinesia | 100% | 95% |
| Rigidity | 100% | 90% |
| Levodopa response | Initial good | Initial good |
Rapid Progression
Early Cognitive Decline
Atypical Features
Age 40-50: First motor symptoms
↓
Age 45-55: Diagnosis, good levodopa response
↓
Age 50-60: Motor fluctuations develop
↓
Age 55-65: Dyskinesias, cognitive changes
↓
Age 60-70: Dementia, severe disability
↓
Age 65-75: Mortality
| Finding | Description |
|---|---|
| Lewy bodies | Abundant, widespread |
| Neuronal loss | Substantia nigra, locus coeruleus |
| Nerve terminal loss | Striatum, cortex |
| Amyotrophic changes | Motor cortex |
Standard PD treatments apply:
| Approach | Target | Status |
|---|---|---|
| Anti-alpha-synuclein antibodies | Passive immunization | Phase 2/3 |
| Small molecule inhibitors | Aggregation | Preclinical |
| Gene therapy | Reduce SNCA expression | Preclinical |
| ASO therapy | SNCA mRNA | Preclinical |
| Agent | Company | Mechanism | Phase |
|---|---|---|---|
| Cinpanemab (BIIB054) | Biogen | Anti-α-syn antibody | Phase 2 |
| Prasinezumab (RO7046015) | Roche | Anti-α-syn antibody | Phase 2 |
| UB-312 | Vaxart | α-syn vaccine | Phase 1 |
| Model | Phenotype | Notes |
|---|---|---|
| SNCA A53T transgenic mouse | Age-dependent motor deficits, α-syn pathology | Most used |
| SNCA A53T knock-in mouse | Mild phenotype | Subtle changes |
| SNCA A53T C. elegans | Aggregation | Rapid screening |
The study of Snca A53T has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.